Edition:
United Kingdom

People: Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

10.95USD
19 Jul 2019
Change (% chg)

$-0.62 (-5.36%)
Prev Close
$11.57
Open
$11.66
Day's High
$11.70
Day's Low
$10.70
Volume
975,633
Avg. Vol
515,308
52-wk High
$48.25
52-wk Low
$10.70

Rolfe, Lindsey 

Dr. Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM., is Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer of the Company. Dr. Rolfe has served as our Executive Vice President of Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer since August 2015. Dr. Rolfe joined Clovis in April 2010 and served as Senior Vice President of Clinical Development until her promotion. Dr. Rolfe has 20 years of drug development experience and previously served in senior oncology development roles at Celgene Corporation, Pharmion Corporation (acquired in 2008), Cambridge Antibody Technology, UCB Inc. and Celltech Group plc. Dr. Rolfe qualified in medicine at the University of Edinburgh. She undertook post graduate medical training in London, U.K. and obtained her post-graduate internal medicine qualification as a Member of the Royal College of Physicians (MRCP). She has specialist accreditation in Pharmaceutical Medicine from the U.K. General Medical Council and is a Fellow of the Faculty of Pharmaceutical Medicine.

Basic Compensation

Total Annual Compensation, USD 682,225
Restricted Stock Award, USD 642,730
Long-Term Incentive Plans, USD --
All Other, USD 494,056
Fiscal Year Total, USD 1,819,010

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ginger Graham

357,479

Patrick Mahaffy

6,267,460

Gillian Ivers-Read

1,764,020

Daniel Muehl

1,509,580

Paul Gross

--

Ann Bozeman

--
As Of  31 Dec 2018